Urol. praxi, 2013; 14(3): 115-118

Current diagnosis and treatment of locally advanced prostate cancer

MUDr.Milan Král, Ph.D., MUDr.Michal Grepl, Ph.D., doc.MUDr.Vladimír Študent, Ph.D.
Urologická klinika LF UP a FN, Olomouc

Despite decrease of locally advanced prostate cancers due to early detection programs, both urologists and oncologists are facing not

negligible number of such patients. Their therapy often needs specific approach. While, previously, these advanced stages of cancers

were matter of radiotherapy, nowdays radical prostatectomy plays an important role because of optimistic oncologic and functional



results: This review presents complex insight into diagnostics and therapy of locally advanced prostate cancers.

Keywords: prostate cancer, therapy, radical prostatectomy, radiotherapy, hormonal treatment

Published: July 15, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Král M, Grepl M, Študent V. Current diagnosis and treatment of locally advanced prostate cancer. Urol. praxi. 2013;14(3):115-118.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90. Go to original source... Go to PubMed...
    2. www.svod.cz.
    3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. Cancer J Clin 2012; 62: 10-29.
    4. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280(11): 969-974. Go to original source... Go to PubMed...
    5. Ward JF, Slezak JM, Blute ML, et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005; 95(6): 751-756. Go to original source... Go to PubMed...
    6. Freedland SJ, Csathy GS, Dorey F, et al. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. J Urol 2002; 167(2 PT 1): 516-520. Go to original source... Go to PubMed...
    7. Tempany C, Franco F. Prostate MRI: Update and current roles. Applied Radiology 2012; 41(3): 17-22. Go to original source...
    8. Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, Heijmink SW, Hoskin PJ, Kirkham A, Padhani AR, Persad R, Puech P, Punwani S, Sohaib AS, Tombal B, Villers A, van der Meulen J, Emberton M. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol. 2011; 59(4): 477-494. Go to original source... Go to PubMed...
    9. Barta J, Ryznarova Z, Klezl P, Zátura F, Adamova M, Kašpar M, Novák J. Postavení magnetické rezonance a magnetické rezonanční spektroskopie v diagnostice karcinomu prostaty. Ces Urol 2010; 14(3): 186-196.
    10. Mocikova I, Babela J, Balaz V. Prostate cancer - the role of magnetic resonance imaging. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012; 156(2): 103-171. Go to original source... Go to PubMed...
    11. Abdollah F, Sun M, Schmitges J, Thuret R, Bianchi M, Shariat SF, Briganti A, Jeldres C, Perrotte P, Montorsi F, Karakiewicz PI. Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics. J Urol. 2012; 188(1): 73-83. doi: 10.1016/j.juro.2012.03.005. Epub 2012 May 12. Go to original source... Go to PubMed...
    12. Van Poppel H, Joniau S.¸An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. Eur Urol. 2008; 53(2): 253-259. Epub 2007 Oct 12. Go to original source... Go to PubMed...
    13. Hsu CY, Joniau S, Oyen R, Roskams T, Van Poppel H. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol. 2007; 51(1): 121-128; discussion 128-129. Epub 2006 Jun 9. Go to original source... Go to PubMed...
    14. Briganti A, Joniau S, Gontero P, Abdollah F, Passoni NM, Tombal B, Marchioro G, Kneitz B, Walz J, Frohneberg D, Bangma CH, Graefen M, Tizzani A, Frea B, Karnes RJ, Montorsi F, Van Poppel H, Spahn M. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. Eur Urol. 2012; 61(3): 584-592. Go to original source... Go to PubMed...
    15. Bertz S, Schmitz-Dräger BJ, Protzel C, Hartmann A. Intraoperative frozen section diagnosis of the genitourinary tract. Pathologe. 2012; 33(5): 441-449. Go to original source... Go to PubMed...
    16. Simon MA, Kim S, Soloway MS. Prostate specific antigen recurrence rates are low after radical retropubic prostatectomy and positive margins. J Urol. 2006; 175(1): 140-144; discussion 144-145. Go to original source... Go to PubMed...
    17. Briganti A, Chun FK, Salonia A, Gallina A, Farina E, Da Pozzo LF, Rigatti P, Montorsi F, Karakiewicz PI. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. BJU Int. 2006; 98(4): 788-793. Go to original source... Go to PubMed...
    18. Heidenreich A, Ohlmann CH, Polyakov S. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol. 2007; 52(1): 29-37. Epub 2007 Apr 11. Go to original source... Go to PubMed...
    19. Van Baelen A, Mottet N, Spahn M, Briganti A, Gontero P, Joniau S. Sense and nonsense of an extended pelvic lymph node dissection in prostate cancer. Adv Urol. 2012; 2012: 983058. Go to original source... Go to PubMed...
    20. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, Matveev V, Mottet N, van der Kwast TH, Wiegel T, Zattoni F. Guidelines on prostate cancer. EAU, 2012 ed.
    21. Berglund RK, Tangen CM, Powell IJ, Lowe BA, Haas GP, Carroll PR, Canby-Hagino ED, deVere White R, Hemstreet GP 3rd, Crawford ED, Thompson IM Jr, Klein EA. Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109. Urology. 2012; 79(3): 633-637. Go to original source... Go to PubMed...
    22. Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, Blute ML, Buyyounouski MK. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. 2011; 117(13): 2883-2891. Go to original source... Go to PubMed...
    23. Mitchell CR, Boorjian SA, Umbreit EC, Rangel LJ, Carlson RE, Karnes RJ. 20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer. BJU Int. 2012; 110(11): 1709-1713. Go to original source... Go to PubMed...
    24. Odrážka K, Doležel M, Vaňásek J. Moderní metody zevní radioterapie v léčbě karcinomu prostaty. Ces Urol 2010; 14(2): 81-91.
    25. Roach M 3rd, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich MV. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008; 26(4): 585-591. Go to original source... Go to PubMed...
    26. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Billiet I, Torecilla JL, Pfeffer R, Cutajar CL, Van der Kwast T, Collette L. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010; 11(11): 1066-1073. Go to original source... Go to PubMed...
    27. Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, Gospodarowicz M, Sanders K, Kostashuk E, Swanson G, Barber J, Hiltz A, Parmar MK, Sathya J, Anderson J, Hayter C, Hetherington J, Sydes MR, Parulekar W. NCIC CTG PR.3/MRC UK PR07 investigators. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011; 378(9809): 2104-2111. Go to original source... Go to PubMed...
    28. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklund F, Foss? SD, Scandinavian Prostate Cancer Group Study 7, Swedish Association for Urological Oncology 3. Lancet. 2009; 373(9660): 301-381. Go to original source... Go to PubMed...
    29. Sridharan S, Warde P. The importance of local control in high-risk locally advanced prostate cancer. Curr Oncol. 2012; 19(Suppl 3): S6-S12. Go to original source... Go to PubMed...
    30. Abrahamsson PA. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2010; 57(1): 49-59. Go to original source... Go to PubMed...
    31. Calais da Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA, Kirkali Z, Calais da Silva FM, Robertson C. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol. 2009; 55(6): 1269-1277. Go to original source... Go to PubMed...
    32. Studer UE, Whelan P, Albrecht W, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European organisation for research and treatment of cancer (EORTC) trial 30891. J Clin Oncol 2006; 24: 1868-1876. Go to original source... Go to PubMed...
    33. Studer UE, Collette L, Whelan P, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008; 53: 941-949. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.